

METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES OF
RECOMBINANT α -L-IDURONIDASE

ABSTRACT

- 5 The present invention provides a formulation comprising a pharmaceutical composition comprising a human recombinant α -L-iduronidase or biologically active or muteins thereof with a purity of greater than 99%, or in combination with a pharmaceutically acceptable carrier. The present invention further provides methods to treat certain genetic disorders including α -L-iduronidase deficiency and
- 10 mucopolysaccharidosis I (MPS I) by administering said formulation.